LB Pharmaceuticals Stock

www.lbpharma.usHealthcare / BioTech & PharmaFounded: 2015

LB Pharmaceuticals is a biotechnology company that is aiming to commercialize central nervous system (CNS) treatments for use in the United States. The company is focused on bringing pharmaceutical treatments into the U.S. market that may have been successful in other countries but have never been approved for use in the U.S. after researching ways designed to improve the treatments. LB Pharmaceuticals was founded in 2015 by Zachary Prensky and Vince Grattan and is headquartered in New York, New York.

Register To Buy and Sell Shares

For more details on financing and valuation for LB Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access LB Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like LB Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

LB Pharmaceuticals investors also invested in these private companies

Pontifax Venture Capital
Vidavo Ventures
Tarnagulla Ventures


Management Team

Zachary Prensky
Co-Founder, Chief Executive Officer & President
Marc Panoff
Chief Financial Officer
Andrew Vaino Ph.D
Chief Scientific Officer
Vincent Grattan
Anna Eramo
Chief Medical Officer

Board Members

Ran Nussbaum
Pontifax Venture Capital

Frequently Asked Questions About LB Pharmaceuticals’ Stock

Can you buy LB Pharmaceuticals’ stock?
LB Pharmaceuticals is not publicly traded on NYSE or NASDAQ in the U.S. To buy LB Pharmaceuticals’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell LB Pharmaceuticals’ stock?
Yes, you can sell stock of a private company like LB Pharmaceuticals. Forge can help you sell your LB Pharmaceuticals stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is LB Pharmaceuticals’ stock price?
LB Pharmaceuticals is a privately held company and therefore does not have a public stock price. However, you may access LB Pharmaceuticals’ private market stock price with Forge Data.
What is LB Pharmaceuticals’ stock ticker symbol?
LB Pharmaceuticals does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

LB Pharmaceuticals closes $75M Series C as it begins PhII schizophrenia trial
LB Pharmaceuticals, a schizophrenia biotech developing a new version of a decades-old medicine, has closed a $75 million Series C raise and it began a Phase II trial last month, a source familiar with the company confirmed to Endpoints News. The New York City biotech has raised a total of about $122 million since it was formed, per the source. The company had raised about $35 million last summer and reached its ultimate $75 million Series C target this month.
Updated on: May 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.